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G protein-coupled receptor kinases (GRKs) and arrestins are key participants in the canonical pathways leading to phosphorylation-dependent
GPCR desensitization, endocytosis, intracellular trafficking and resensitization as well as in the modulation of important intracellular signaling
cascades by GPCR. Novel studies have revealed a phosphorylation-independent desensitization mechanism operating through their RGS-
homology (RH) domain and the recent determination of the crystal structures of GRK2 and GRK6 has uncovered interesting details on the
structure–function relationships of these kinases. Emerging evidence indicates that the activity of GRKs is tightly modulated by mechanisms
including phosphorylation by different kinases and interaction with several cellular proteins such as calmodulin, caveolin or RKIP. In addition,
GRKs are involved in multiple interactions with non-receptor proteins (PI3K, Akt, GIT or MEK) that point to novel GRK cellular roles. In this
article, our purpose is to describe the ever increasing map of functional interactions for GRK proteins as a basis to better understand its
contribution to cellular processes.
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family of seven serine/threonine protein kinases that specifi-
cally recognize and phosphorylate agonist-activated G protein-
coupled receptors (GPCRs). GRK-mediated receptor phosphor-
ylation is one of the well-characterized mechanisms for GPCR
desensitization. Receptor phosphorylation triggers the binding
of arrestins, which block the activation of G proteins, leading to
rapid homologous desensitization (Fig. 1a). As a result of β-
arrestin binding, phosphorylated receptors are targeted for
clathrin-mediated endocytosis, a process that classically serves
to resensitize and recycle receptors back to the plasma
membrane, but that has gained renewed interest since it can
also help promote the activation of additional signaling
pathways by way of arrestins acting as agonist-regulated
adaptor scaffolds [1,2].
Recent findings have also unveiled other interesting features
of this system. For instance, based on results obtained using
GRK-defective mice models, it was postulated that differentFig. 1. Different mechanisms of signalliGRK isoforms could not complement one another since knock-
out mice for a given GRK were defective in certain function that
other GRKs were not able to compensate for [1]. On the other
hand, recent evidence has also shown that depending on the
receptors or the tissues considered and its precise complement
of GRK isoforms, the kinase subtypes involved in desensitiza-
tion and β-arrestin recruitment can also differ [3]. In another
twist to this matter, recent experiments using siRNA suggest
that GRK2 and 3 are more efficient than GRK5 and 6 in
promoting receptor endocytosis by the β-arrestin-clathrin
pathway [4,5] thus uncovering particular functional differences
among isoforms. For many receptors that are substrates for
multiple GRKs, the specificity of GRK-GPCR interaction may
be defined in part by the different cellular distribution and
activity of GRKs at the time of agonist stimulation (reviewed in
[1,6]).
Interestingly, while GRKs preferentially phosphorylate
activated GPCRs, these kinases are also able to phosphorylateng pathways modulation by GRK2.
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receptor substrates such as tubulin, synucleins, phosducin,
ribosomal protein P2, the inhibitory γ subunit of the type 6
retinal cyclic guanosine monophosphate (cGMP) phosphodies-
terase, the β-subunit of the epithelial Na+ channel, the ezrin–
radixin–moesin (ERM) family protein ezrin and other soluble
substrates ([8,9] and references therein). Thus, GRKs may
participate in the regulation of diverse cellular phenomena
through the phosphorylation of substrates that vary functionally.
In addition to these phosphorylation-dependent processes,
GRKs may also contribute to modulate cellular responses in a
phosphorylation-independent manner due to its ability to
interact with a variety of proteins involved in signaling and
trafficking such as Gαq and Gβγ subunits, PI3K, clathrin, GIT,
caveolin, MEK, AKT, and RKIP [8,10–12]. Since the GRKs
interact with multiple signaling proteins involved in essential
biological pathways, this new "interactome" may serve to unveil
novel functional roles for GRKs that could be relevant in human
physiology and disease. The purpose of this article is to review
these novel interactions and the emerging roles for GRKs.
1. The GRK family
GRK family members can be subdivided into three main
groups based on sequence homology:rhodopsin kinase or visual
GRK subfamily (GRK1 and GRK7), the β-adrenergic receptor
kinases subfamily (GRK2/GRK3) and the GRK4 subfamily
(GRK4, GRK5 and GRK6). These kinases share certainFig. 2. Localization of modulatory phosphorylation sites and regions involved in
domains.characteristics but are distinct enzymes with specific regulatory
properties. GRK2, 3, 5 and 6 are ubiquitously expressed in
mammalian tissues, whereas GRK1, 4 and 7 are confined to
specific organs. GRK1 and 7 are expressed in retinal rods and
cones, respectively, and GRK4 is present in testis, cerebellum
and kidney [13–15].
GRKs share a common structural architecture (Fig. 2) with a
well-conserved, central catalytic domain (∼270 aa), similar to
that of other serine–threonine kinases, flanked by an N-terminal
domain (∼185 aa) and a variable-length carboxyl-terminal
domain (∼105–230 aa). The N-terminal domain has been
proposed to be important for receptor recognition, for
intracellular membrane anchoring [16,17] and it also contains
an RH domain (regulator of G protein signalling homology
domain) of ∼120 aa. In the case of GRK2 and GRK3, this
domain can provide a potential mechanism by which GRKs
might regulate GPCR signaling independently of phosphoryla-
tion [18–20] as will be discussed in more detail below. Apart of
bearing a RH domain, the N-terminal region of GRKs displays
several other motifs. Thus, for GRK4-6, phosphatidylinositol
(4,5) biphosphate (PIP2) leads to an increase in the kinase
catalytic activity [21]. More recently, a Gβγ-binding site has
been described in the N-terminal domain of GRK2 [22], which
helps to target GRK2 to the membrane [23].
The C-terminal domain of the GRKs contributes to their
subcellular localization and agonist-dependent translocation by
favouring their interaction with lipids and other membrane
proteins [1,2,6,8,24,25]. The C-terminus of GRK2 and 3interaction with other proteins in the GRK2 and GRK5 subfamilies structural
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for the membrane phospholipid PIP2 and free Gβγ subunits
[25,26]. Since GRK2 and 3 are cytosolic proteins, these
specific interactions could help to maintain a membrane-bound
population of GRK2 prior to the agonist-dependent overt
GRK2 translocation [8]. GRK4 and GRK6 are post-transla-
tionally palmitoylated, leading to a constitutive membrane-
associated localization [21]. It is important also to notice that
GRK4 and GRK6 are expressed as multiple splice-variant
forms that can lead to a different structural domain organiza-
tion [27,28]. GRK5 is also membrane-associated through a
PIP2 binding domain present on its N-terminus and also binds
phospholipids constitutively via its carboxy terminal domain
[29]. Recently, it has been observed that GRK5 contains an
amphipathic helix membrane binding domain, located in its
C-terminal region, important for its function and proper
localization at the membrane [30]. GRK1 and 7 are mostly
membrane associated via a post-translational farnesylation at
their C-termini. Finally, GRKs are substrates for different
kinases, that contribute to modulate kinase activity, localization
and stability [8].
2. Structural features of the GRK family
As mentioned before, the GRK kinase domain is relatively
well conserved among the different subfamilies (∼45%
sequence identity), whereas the N-terminal RH domains display
weak homology (∼27%), and the C-termini have little or no
sequence homology. The control of GRK2 activity and mem-
brane targeting appears to involve intramolecular interactions,
the association of both N- and C-terminal domains of the kinase
with different intracellular targets, as well as post-translational
modifications by other kinases. Prior to the availability of a
three-dimensional structure of GRK2, biochemical and mole-
cular modelling data suggested the existence of regulatory
intramolecular interactions between the N-terminal, C-terminal
and catalytic domains of GRK2 that would keep the kinase in a
constrained, inactive basal state [31]. Disruption of such
intramolecular contacts by GPCR and activators such as Gβγ
would promote conformational changes in the kinase, leading to
its translocation and activation. The crystal structure of GRK2 in
complex with G protein β1γ2 subunits provided new insights
into GRK regulation [32], placing its three distinct regions (RH,
kinase and PH domains) at the vertices of a triangle, as an
excellent example of how multiple modular domains are
integrated in a single molecule to transduce and modulate sig-
naling events.
Similar to what has been observed in P115-RhoGEF and PDZ-
RhoGEF, the RH domain of GRK2 consists of nine α-helices that
are analogous to other RGS domains (aa 20–185) and two
additional α-helices derived from a region between the kinase
and the PH domain (aa 513–547). The RH domain can
interact with both the kinase and the PH domain, suggesting
an important role in the regulation of kinase activity. The
structure of the kinase domain of GRK2 is similar to that
reported for other kinases and, in complex with Gβγ subunits,
appears to lie in a resting conformation through its intimateassociation with the terminal and the bundle subdomain of the
RH domain: the α10-helix of the RH domain contacts with the
β2–β3 and αC–β4 loops of the kinase domain, whereas the
α4–α5 loop of the RH bundle domain contacts the αJ helix of
the kinase domain. These interactions may have a regulatory
role on GRK2 activation.
The PH domain of GRK2, known to be involved in
phospholipid binding and membrane targeting, consists of
seven β-strands and one C-terminal α-helix. In the complex,
the RH–PH domain interface includes the β1 strand and αCT
helix of the PH domain and the α1 and α9 helices of the RH
terminal subdomain, suggesting that an allosteric regulation
might exist between these two domains [32]. Therefore,
changes in the conformation of the RH or PH domains caused
by protein–protein interactions or by phosphorylation could
lead to changes in catalytic activity via their interface with the
kinase domain. Interestingly, GRK2 activity is inhibited when
phosphorylated by MAPK at Ser670, a residue located in the
C-terminal domain, by hampering Gβγ binding [33]. In
contrast, PKA-mediated phosphorylation of GRK2 at residue
Ser685 has the opposite effect by facilitating contacts with
Gβγ subunits and kinase activation [8]. On the other hand, the
tyrosine kinase c-Src phosphorylates GRK2 at several
positions of the RH domain [34,35] which results in profound
functional changes as discussed in the next section.
Recently, the crystal structure of GRK6 in complex with an
ATP analogue has been solved [36] thus allowing comparison
of different GRK subfamilies. While the RH-kinase domain
interaction is maintained, thus suggesting a conserved role for
this interface in stabilizing the inactive conformation of these
kinases, GRK6 crystallized as a dimer utilizing a surface of its
RH domain that is conserved in both GRK4 and GRK1
subfamilies. The presence of this dimerization domain could
be important in kinase function or in the interaction with other
proteins. This crystal structure has further revealed that despite
the lack of sequence and structural conservation at the N- and
C-terminus of GRKs, the catalytic and membrane targeting
sites are similarly arranged in both the GRK4 and the GRK2
subfamilies.
3. Functional role of the RH domain of GRKs
To date, the RH domain of GRK2 has been shown to
specifically interact with Gαq family members, although it
does not stimulate the GTPase activity of Gαq as efficiently
as other classical RGS proteins do [37]. The ability of GRK2
to function as a Gαq GAP appears to be receptor-dependent
[18]. Both GRK2 and GRK3 can interact with Gαq and Gα11
but not with Gαs, Gαi, Gαo or Gα12/13 [18,19,38]. More
recent experiments have demonstrated that GRK2 is also able
to interact with Gα14 but not with Gα16 [38]. No interaction
of the RH domains of GRK5 and GRK6 with Gα proteins
has been described [18], although this remains an exciting
possibility.
The role of GRK2 in regulating Gα signaling remains to be
fully elucidated. Thus, although GRK2 has a poor Gαq-GAP
activity, its RH domain may function as an efficacious effector
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GPCR or its corresponding effector [39]. In this sense, the RH
domain of GRK2 is able to inhibit Gαq-mediated phospholipase
C activity both in vitro and in intact cell assays, and is more
potent a blocker than RGS4 [18,19]. This inhibition is observed
upon the expression of the GRK2-RH domain alone and seems
to be independent of receptor phosphorylation, what has laid the
basis to suggest it is caused by sequestration of Gαq by protein–
protein interactions. This provides an additional mechanism of
regulation of receptor signaling by GRKs at the G-protein level
(Fig. 1b). Indeed, several recent publications have implicated
GRKs in phosphorylation-independent desensitization of var-
ious GPCRs such as endothelin A and B, thromboxane A2, α1b-
adrenergic, M1 and M3 muscarinic cholinergic, parathyroid
hormone, thyrotropin-realising hormone (TRH), 5-hydroxy-
tryptamine 2C, metabotropic glutamate receptor-1a (mGluR1a),
type 1A angiotensin II and human H1 histamine receptors
(reviewed in [39–43]). For many of these receptors, expression
of the GRK2-RH domain is sufficient to attenuate signaling in
the absence of phosphorylation. Interestingly, a D110A-GRK2
mutant impaired in Gαq/11 binding [44] is unable to antagonize
both basal and agonist-stimulated mGluR1a signaling despite
interacting normally with the receptor. However, it must be
stressed that for many receptors both the phosphorylation and
non-phosphorylation mechanisms are important for effective
signal attenuation. In this line, Dhami et al., have shown that a
mutant in the α11 helix of the GRK2 RH domain that is unable
to bind receptor [32] but competent to interact with Gαq did not
attenuate mGluR1a signaling [45]. Thus, it has been suggested
that phosphorylation-independent desensitization is not only the
consequence of non-specific sequestration of Gαq/11 by the
GRK2 RH domain, but that the binding of GRK2 to both
receptor and G protein is required to occur in an adequate
molecular context [39].
The majority of the conserved residues within the hydro-
phobic core of the consensus RH domain are shared by other
GRK family members. Although it is possible that similar RH
functions can be exerted by other GRKs, this issue has yet to be
demonstrated. In this sense, the attenuation of mGluR1a-
stimulated PLCβ activity by GRK4 and GRK5 seems to be
phosphorylation-dependent in contrast to what has been shown
for GRK2 [39], whereas overexpression of GRK6 leads to
mGluR1a phosphorylation in the absence of attenuated receptor
signaling [46].
The regulation of GRKs by phosphorylation has been
extensively reviewed [8]. As we mentioned before, tyrosine-
phosphorylation of GRK2 increases its activity towards both
soluble and membrane-bound substrates, suggesting a direct
effect on its catalytic activity [34]. We have shown that the
tyrosine residues critical for c-Src modification are present
within the RH region of GRK2 (aa 86 and 92) and close to the
calmodulin-binding domain (aa 13) [35]. Since it has been
described that the RH domain of GRK2 interacts with its
catalytic domain keeping the kinase in an inactive conformation
[31,32], it is tempting to speculate that tyrosine phosphorylation
of these residues could alter interdomain contacts and thus
modify its activity. In addition, this tyrosine phosphorylationappears also to enhance the interaction between GRK2 and Gαq
[47]. c-Src kinase activity increases GRK2/Gαq interaction and
tyrosine phosphorylation of GRK2 is strictly required for this
effect, since it is not observed with a phospho-tyrosine defective
GRK2 mutant. Conversely, a mutant that mimics GRK2
tyrosine phosphorylation in these residues displays an increased
interaction with Gαq. Consistent with a physiological role of
this modulatory mechanism, activation of the muscarinic
receptor M1, a Gαq-coupled receptor, promotes an increase in
GRK2/Gαq co-immunoprecipitation that parallels the enhanced
GRK2 phosphorylation on tyrosine residues. Moreover, c-Src
activation enhances inhibition of the Gαq/phospholipase Cβ
signaling pathway in intact cells, in a GRK2-tyrosine-
phosphorylation-dependent manner. These findings suggest a
feedback mechanism by which phosphorylation of GRK2 by c-
Src increases both GRK2 kinase activity towards GPCRs and its
specific interaction with Gαq subunits, leading to a more rapid
switch off of Gαq-mediated signaling [47].
Recently, the crystal structure of GRK2 in complex with both
the Gβγ and Gαq subunits has been solved [48]. The residues
of GRK2 in the interface with Gαq are consistent with those that
were first identified in biochemical mutational studies and are
located primarily in the C-terminus of the α5 helix of the GRK2
RH domain. It is important to notice that some of these
mutations can impair phosphorylation-independent desensitiza-
tion [42,45,49]. This novel-binding site is distinct from Gα
binding sites for other RGS proteins and has been described as
“C” site [44]. Moreover, none of the mutations in Gαq that
affected GRK2 binding can interfere with the binding to other
RGS proteins. Rather, residues in Gαq involved in its
interaction with GRK2 are analogous to those implicated in
association to its classical effector PLCβ. In conclusion, GRK2
RH domain binds Gαq in a manner more similar to an effector-
like interaction than an RGS-like one, thus making it possible to
suggest a role for GRK2 as an effector of Gαq signaling-
mediated pathways (Fig. 1b).
By contrast, in GRK6, the analogous α5 helix important for
Gα interaction is shorter than the one in GRK2, and the
residues analogous to those relevant for binding to Gαq are not
present [36,44]. Furthermore, the α5–α6 loop, that has an
important role in binding Gαi, Gαt and Gαq subunits in RGS
proteins [50,51], has a different structure in GRK6, suggesting
that the GRK6 RH domain cannot serve as a GTPase-activating
protein for Gq subunits, at least in the same way RGS proteins
act [36].
4. Other GRK binding partners and functional roles
Several GRK binding partners have recently been identified
by using different biochemical approaches and yeast-two hybrid
screens (see Table 1 and Fig. 2 for a summary of these
interactions and their localization in the GRK2 or GRK5
subfamilies structural domains). From a functional point of
view, the discovery of numerous GRK-interacting proteins
(particularly for GRK2) has revealed a much more complex
scenario for both GRK regulation (Fig. 3) and potential
biological roles (Fig. 1b) that are discussed below.
Fig. 3. Regulators of GRK2 activity.
Table 1
Functional consequences of the interaction of GRKs with cellular proteins
GRK interacting protein Functional effect References
Gβγ Gβγ scavenger [24]
Gq/11 Inhibition of PLCbeta activity [17]
Caveolin Inhibition of GRK activity [52]
RKIP Inhibition of GRK activity [9]
Calmodulin Inhibition of GRK activity [55]
Clathrin GPCR internalization [66]
α-actinin Inhibition of GRK activity [7]
Actin Inhibition of GRK activity [56]
Microsomal component Inhibition of GRK activity [16]
PI3K β-adrenoceptor internalization [60,61]
Akt Inhibition of Akt activity [11]
Hsp90 GRK folding and maturation [68]
GIT Scaffold for receptor endocytic
complexes
[63]
MEK1 Inhibition of chemokine-mediated
induction of ERK activity
[10]
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Caveolin binding motifs on GRK2 are located in the PH
domain (residues 567–584) and in the N-terminal domain
(residues 63–71); the latter domain is present not only in the
highly homologous GRK3 but also in GRK5 [52] thus allowing
the binding to caveolin of those GRK members that lack the PH
domain. Caveolins serve as scaffolds for a variety of signaling
molecules including GPCR, different MAPK, and G proteins
and may help to curtail and/or compartmentalize their signaling.
GRK2-mediated phosphorylation is inhibited when bound to
caveolin-1 or -3, suggesting that caveolins may play a role in
controlling basal GRK activity. In support of this notion, GRK2
upregulation parallels a decline in caveolin-1 expression with
aging in the dysfunctional vasculature [53], making feasible that
changes in caveolin expression might underlie the aberrant
GRK activity reported in some human diseases. Alternatively,
or in addition, the GRK/caveolin association may facilitate the
interaction of these kinases with other signaling or regulatory
molecules.
4.2. Calcium-binding proteins
Cellular calcium levels also appear to modulate GRK activity
by means of the interaction of calcium-sensing proteins with
different GRKs (reviewed in [54]). Recoverin, a calcium-
binding protein present in photoreceptor cells, binds to and
inhibits GRK1, thus providing a mechanism for modulating its
activity during light (high calcium) or dark (low calcium)
situations. On the other hand, calmodulin, a universal mediator
of calcium signals, can inhibit the activity of GRK2–6, although
with varying potencies [55]: GRK5 is very sensitive to the
presence of calcium-bound calmodulin (IC50 ∼40 nM),
whereas GRK2 is only affected at high concentrations (IC50
∼2 μM). Interaction of calmodulin with GRK2 at sites located
at both the N- and C-terminal domains of the kinase (residues
18–37 and 593–689) directly inhibits its activity. It has also
been shown that PKC-mediated phosphorylation of GRK2
relieves the inhibitory effect exerted by calmodulin besidespotentiating kinase interaction with the plasma membrane,
which results in an increased activity towards receptors. On
contrast, catalytic activity of GRK5 is markedly inhibited by
PKC (reviewed in [8]). By displacing bound actin from GRK5,
calmodulin can increase its capacity to phosphorylate soluble
but not receptor substrates [56]. In addition, calmodulin can
promote a pattern of autophosphorylation different from that
elicited by lipids [54,55,57] that inhibits catalytic activity. Due
to its high affinity for calmodulin, it is suggested that GRK5
would be inhibited in most cell types as soon as calcium
concentration rises, while the inhibition of GRK2, with lower
affinity for calmodulin, may take place only in cells where
calmodulin is highly expressed. The functional consequences of
differential regulation of GRK subtypes by calmodulin can be
hypothesized: a number of GPCR substrates of GRK2 and 5, by
promoting fluctuations in intracellular calcium concentrations
would trigger a calmodulin (and PKC)-mediated negative
feedback loop for GRK5, but not GRK2, homologous
desensitization mechanisms.
In addition, it has been also reported that GRK2 interacts
with the neuronal calcium sensor-1 (NCS-1), resulting in the
modulation of GRK2-mediated desensitization of D2 dopamine
receptors [58]. Moreover, GRK2 can also phosphorylate
DREAM, an important Ca2+-regulated cellular mediator
(Ruiz-Gómez et al., submitted) The study of the functional
relationships between GRKs and calcium-binding proteins thus
emerges as an interesting field of research in the future.
4.3. RKIP
Other relevant novel partner of GRK2 is the Raf kinase
inhibitor protein RKIP [10]. After stimulation of GPCR, PKC
phosphorylation of RKIP on Ser 153 increases its binding
affinity towards GRK2 and dissociation from its known target,
Raf-1, prolonging ERK activation. This association of RKIP
with GRK2 has been shown to block kinase activity. An
augmented level of RKIP would then lead to reduced GRK2
activity thus impairing agonist-triggered down-regulation
processes and prolonging receptor signaling. This finding may
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instance in some neoplasic disorders where RKIP has emerged
as a relevant tumor suppressor gene [59].
4.4. PI3K
Another GRK-interacting protein is the phosphoinositide 3-
kinase (PI3K). Rockman and co-workers have shown a possible
involvement of PI3Kγ in the regulation of β-adrenoceptor
internalization through the interaction with GRK2, that mediates
PI3Kγ recruitment to the membrane after agonist stimulation
[60]. More recently they provided evidence for a direct protein–
protein interaction between PI3Kγ and GRK2, showing that the
region of the PI3K molecule important for this interaction is the
197 aa PIK domain [61]. Moreover, the overexpression of the
PIK domain inhibits PI3K–GRK2 interaction and markedly
attenuates β2-adrenoceptor endocytosis, probably by a loss in
receptor-associated PI3K activity that impairs the ability of the
agonist-occupied receptor/PI3K complex to generate the D-3
phospholipid molecules required for the dynamics of receptor
endocytosis. In this regard, disruption of the GRK2/PI3K
complex in vivo by transgenic PIK overexpression preserves β-
adrenoceptor signaling despite prolonged cathecolamine admin-
istration, reversing the β-adrenoceptor abnormalities and
restoring contractility in failing cardiomyocytes to normal
values [62]. Thus, PIK-domain interactions and/or PI3K
membrane targeting appears to play an important role in the
processes of βAR desensitization and down-regulation that are
characteristic of heart failure.
4.5. Akt
The serine–threonine kinase Akt has also been reported to
associate directly with GRK2 through the GRK2 C-terminus (aa
492–689), resulting in Akt inhibition. GRK2-mediated inhibi-
tion of Akt phosphorylation seems to be agonist-dependent,
although the exact mechanisms involved are not well
established. Interestingly, GRK2 is up-regulated in vascular
diseases where inhibition of Akt has been observed [12].
4.6. GIT proteins
Other novel binding proteins for GRKs are the ubiquitous
multifunctional proteins GIT1 and GIT2, which were initially
identified as binding partners for GRK2, 3, 5 and 6 in a yeast
two-hybrid screen [63]. The GIT family of proteins displays a
complex domain structure, including a zinc-finger motif, three
ankyrin repeats present in the N-terminal region of the protein, a
Spa2-homology domain (SHD), a coiled-coiled domain and a
paxillin-binding site (PBS). As a result of such multidomain
architecture, GIT proteins can interact with a variety of
signaling molecules involved in multiple cellular processes
such as cytoskeletal dynamics, membrane trafficking, cell
adhesion and signal scaffolding [64]. Interestingly, GIT proteins
display GAP activity towards the ADP-ribosylation factor
(ARF) family of small GTP-binding proteins [65], mainly
ARF1 and ARF 6, by means of an N-terminal GTP-aseactivating factor (ARF-GAP) domain. Consistently with the
role of ARF6 in vesicle budding and membrane trafficking from
the plasma membrane, overexpression of GIT1 in cells (what
would favour ARF6 inactivation) strongly impairs endocytosis
of several GPCRs, while endogenous GIT1 has been shown to
be strictly required for receptor internalization, as transient shut
off of ARFs is a necessary step for vesicle formation. Although
the functional consequences of GRKs/GITs interaction is still
unclear and the precise domains involved in their association
need to be defined, it is tempting to suggest that GRKs may
function as anchoring proteins for GIT molecules recruiting
them to the vicinity of receptor complexes that undergo
endocytosis, in a way similar as β-arrestin does with ARNO
molecules. On the other hand, given the scaffold role of GIT
proteins and their diverse implications in cellular signaling, it is
also possible that the recruitment of GRK to GIT complexes
might help GRKs to engage in novel functional and/or
regulatory interactions.
4.7. Clathrin
In line with a more direct role of GRKs in receptor
internalization apart from enhancing β-arrestin recruitment,
clathrin has been reported to bind GRK2 through a clathrin-
box located in the C-terminal domain of the kinase. This
interaction seems to be involved in agonist-promoted inter-
nalization of certain GPCR via a dynamin dependent-
mechanism [66]. GRK2 has been detected in endosomal
vesicles upon β2-adrenoceptor activation, consistent with a
role in receptor sequestration [67]. Interestingly however,
clathrin binding to GRK2 is able to modulate its activity. Since
GRK2 has a growing list of non-receptor substrates, it is
possible that clathrin may regulate the extent of their phos-
phorylation [8].
4.8. MEK/ERK interface
Recently, we have found, using GRK2-transfected cells or
splenocytes from heterozygous GRK2 mice, that elevated levels
of GRK2 can inhibit chemokine-mediated induction of ERK
activity and, on the contrary, that decreased levels of GRK2
promote a more robust ERK activation upon agonist treatment.
Neither the kinase activity of GRK2 nor its interaction with G
protein subunits is necessary for this inhibitory effect and no
changes were observed in the extent of MEK activation in our
experimental settings. Interestingly, we have found that GRK2
and MEK1 are present in the same multimolecular complex and
that this interaction correlates with an inhibition of ERK
activation, that involves a direct or coordinate interaction with
MEK [11]. Thus, this association seems to be important in the
control of chemokine induction of MAPK activation. By
binding to MEK, GRK2 could interfere (at the cellular level or
at defined cellular locations) with MEK association to proteins
important for its cellular compartmentalization, internalization,
or activity, such as MEK-ERK scaffolds. Therefore, changes in
GRK2 expression in pathological conditions would alter
chemokine receptor signaling at different levels.
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Finally, several GRKs can interact with the heat shock
protein 90 (Hsp90), a protein chaperone that binds to a variety
of kinases, GPCR and G-proteins. This interaction plays an
important role in GRK folding and maturation [68] although its
putative role in GPCR signaling remains to be determined.
4.10. Phosphorylation of non-receptor substrates
As we already mentioned, GRK2 can also phosphorylate
non-receptor substrates such as phosducins, synucleins, tubulin,
ribosomal protein P2, ezrin (reviewed in [6]) and receptor
regulated Smads (R-Smads) [69], what would be consistent
with an effector role for GRKs. For instance, phosphorylation of
non-receptor substrates such as tubulin or ezrin could facilitate
clathrin-mediated endocytosis and cytoskeletal rearrangements
that may play a role in cellular migration. Upon TGF-beta
stimulation, GRK2 can associate to and phosphorylate R-Smads
in their carboxyl-terminal, preventing nuclear translocation of
the Smad complex, leading to the inhibition of TGF-beta signal
transduction [69]. Recently, GRK5 has been found to contain a
DNA-binding nuclear localization sequence (NLS) that allows
its binding to DNA and its localization in the nucleus upon
GPCR activation [70].
5. Concluding remarks
The number of proteins with which GRKs interact (“inter-
actome”) has increased over the last years unveiling novel
mechanisms of regulation as well as suggesting additional
biological functions for this family of kinases. However, the
modulation of such interactions by extracellular signals, their
physiological role and their spatial and temporal integration
with other GRK functions remain to be established. On the other
hand, the potential physiopathological implications arising from
this new interaction map are far from being elucidated.
Alterations in GRKs activity and expression have been found
in cardiovascular system diseases as congestive heart failure or
hypertension, immune and inflammatory processes as rheuma-
toid arthritis or multiple sclerosis, thyroid gland pathologies,
opioid addiction, retinitis pigmentosa, ovarian cancer and cystic
fibrosis among other pathologies (reviewed in [6,8,71]). A
better knowledge of the GRK interactome and its functional
consequences will help us better understand the mechanisms
and signals governing the expression and activity levels of
different GRKs and their alterations during the progression of
several diseases, as well as to asses the impact of such
alterations in the complex integrated network of GRK cellular
functions.
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